Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19717646 | 0.88 | CYP1A2 (0.34) | CYP2D6CYP2C9CYP1A2USP2CYP2C19 | |
| SCHEMBL3327476 | 0.81 | DPP4 (0.37) | USP2ALDH1A1CYP3A4DPP4DPP7 | |
| SCHEMBL18711622 | 0.81 | USP2 (0.46) | CYP2D6CYP2C9CYP1A2USP2CYP2C19 | |
| SCHEMBL933548 | 0.79 | USP2 (0.41) | CYP2D6CYP2C9CYP1A2USP2CYP2C19 | |
| SCHEMBL18701844 | 0.76 | EPHX2 (0.42) | CYP2D6CYP2C9CYP1A2SPRALDH1A1 | |
| SCHEMBL8513076 | 0.76 | SPR (0.30) | SPR | |
| SCHEMBL3924590 | 0.75 | HSD11B1 (0.42) | CYP2D6CYP2C9CYP1A2USP2CYP2C19 | |
| SCHEMBL751237 | 0.75 | USP2 (0.39) | CYP2D6CYP2C9CYP1A2USP2SPR | |
| SCHEMBL1125850 | 0.74 | DPP4 (0.37) | CYP2D6CYP2C9CYP1A2SPRALDH1A1 | |
| SCHEMBL23672439 | 0.74 | USP2 (0.33) | CYP2D6CYP2C9CYP1A2USP2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054361-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| US-10889591-B2 | PDE9 inhibitor and use thereof | NANJING TRANSTHERA BIOSCIENCES CO. LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| US-20200115384-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889591-B2 | PDE9 inhibitor and use thereof | PDE3A, PDE9A, PDE3B | CYP2D6 515/4885CYP2C9 59/4885CYP1A2 331/4885 |
| US-20200115384-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE3A, PDE9A, PDE3B | CYP2D6 515/4885CYP2C9 59/4885CYP1A2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.